Mashup Score:123
NatureImmunosuppressive niche engineering at the onset of human colorectal cancer – Nature Communications - 1 week
Mashup Score:123
# crctrialschat
Mashup Score:110
NatureTing and colleagues report the safety and efficacy of combined radiation and immunotherapy in a phase II trial on patients with MSS colorectal or...
-
A8-5 A p2 trial by @aparna1024 explored combined ipi + nivo with immunostimulatory doses of RT (24 Gy in 3 fractions) to elicit enhanced systemic anti-tumoral immune response for patients with M1 CRC or PDAC. https://t.co/AboCYs8JXg #CRCTrialsChat - view on twitter
More coverage:
#crctrialschat
Neoadjuvant chemoradiotherapy is the standard treatment for locally advanced rectal cancer, with modest benefits on tumor regression and survival. Since chemoradiotherapy combined with immune...
-
A8-4 ❓ ICI timing Ongoing trials: 📌VOLTAGE-A: LC-CRT → Nivo → surgery 📌NCRT-PD-1-LARC: LC-CRT + Tislelizumab (anti-PD-1) → surgery Primary endpoint= complete response 🔥Early results favorable with 30-50% pCR! https://t.co/hRLnPEzSj9 https://t.co/hRLnPEzSj9 #CRCTrialsChat - view on twitter
More coverage:
#crctrialschat
Integration of mathematical modeling, ecological analyses of patient biopsies, and neoantigen heterogeneity suggests recruitment of immunosuppressive cells is key to initializing transformation from adenoma...
A2-1 📌🔥tumors have lots of immune cells 📌🧊tumors have very little immune cell infiltration Here’s 👇a great model illustrating the origins of CRC. As adenomas progress to carcinomas it becomes less immunogenic & more immunosuppressive. https://t.co/CIHJuGZtk8 #CRCTrialsChat https://t.co/CIHJuGZtk8 - view on twitter